Linked In
News In
Linked In

You are viewing your 1 complimentary article.

Register now to receive full access.

Already registered?

Login | Join us now

Plant Health Care shares tumble as Arysta deal unwinds

Twitter Linkedin eCard

Plant Health Care has seen its share price drop sharply, as a deal to produce agricultural chemical products with crop protection group Arysta breaks up.

The two companies have terminated to use biological stimulants produced by Plant Health Care in combination products, citing weak crop prices.

Plant Health Care shares dropped nearly 15% on the news.

'Weak crop prices'

Plant Health Care ascribed the unsuccessful launch of the new product to "challenging conditions in agricultural markets driven by weak crop prices, especially in row crops".

The company also noted the "focus on the organizational merger of Chemtura AgroSolutions, Agriphar and Arysta LifeScience".

In 2015, Arysta LifeScience was acquired by Platform Specialty Products for $3.5bn, after terminating a planned floatation on the New York stock exchange.

Platform, produces specialty chemicals and provides of technical services, had previously bought Chemtura AgroSolutions and Agriphar Group.

Platform rolled the existing agricultural product groups into Arysta following the takeover.

Protein technology

The termination of the deal has ended product development on a product that was intended to combine Plant Health Care's patanted Harpin technology, as well as crop protection products made by Arysta, for application to row crops, such as soybeans and corn.

Harpin is a biological stimulant. The proteins in the product are also produced by plant pathogens.

Crops respond to the application of these proteins as if they were under attack from disease, activating defensive and growth responses.

Plant Health Care says that the defensive responses triggered by the proteins "help the plants survive the stresses and other threats the diseases present".

Brazil development

Plant Health Care restated its commitment to "accessing row crop markets in the U.S. with Harpin as both a straight product and in combination with mixture partners".

Arysta will continue to work with Plant Health Care on a specialist sugarcane application product.

According to the deal, signed a year ago, Arysta will evaluate the sugarcane protein technology for use in Brazil.

"Pending local registration and consistent, reliable test results in the evaluation program, first sales of the product are anticipated in the 2017 crop season," Arysta said at the time.

Shares fall

Plant Health Care also said that it would continue to "seek other opportunities for global collaboration".

Shares in Plant Health Care were down 12.6% at £74.75 in afternoon deals in London.

Platform Speciality products shares were down 0.1% at $12.32 in New York.

By William Clarke

Twitter Linkedin eCard
Related Stories

Will protein prices fight back against fat in dairy markets?

Prices of fats remain elevated against protein values in dairy - at a time when the opposite is true in markets for oilseed products

World phosphate, potash shipments to grow in 2018, helped by Chinese needs

Mosaic forecasts further demand expansion, as it heralds a "transformational year" for its own fortunes, after a 2017 marred by a one-time tax charge

Deere lifts sales hopes - even as it unveils biggest loss in 25 years

The maker of John Deere tractors flags "strengthening" market conditions, but swallows a huge writedown prompted by US tax retorms

Plant Impact agrees takeover by Croda, after failure of Bayer contract

The crop enhancement group, floored by the failure of a supply deal with Bayer, agrees a takeover by a maker of chemicals from anti-wrinkle creams to floor coatings
Home | About | RSS | Commodities | Companies | Markets | Legal disclaimer | Privacy policy | Contact

Our Brands: Comtell | Feedinfo | FGInsight

© 2017 and Agrimoney are trademarks of Agrimoney Ltd
Agrimoney is part of AgriBriefing Ltd
Agrimoney Ltd is registered in England & Wales. Registered number: 09239069